ClinicalTrials.gg
Status unknownNCT05397938Updated May 31, 2022

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

A Phase 2 interventional study of JMT103 and Alendronate sodium in Glucocorticoid Induced Osteoporosis, sponsored by Shanghai JMT-Bio Inc.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Shanghai JMT-Bio Inc. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
231
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
18th of 57
231 · median 120
Started
2022
with 4 others
Phase 2
3 of 87
1 open now
Registered
48th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 18th largest by planned enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 48th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, positive-controlled phase II interventional study designed to evaluate the efficacy and safety of JMT103 in the treatment of glucocorticoid induced osteoporosis patients. Patients will be enrolled and randomized to 3 treatment groups, JMT103 60 mg group (and alendronate sodium tablet placebo), JMT103 90 mg group (and alendronate sodium tablet placebo), and alendronate sodium 70 mg active comparator group (and JMT103 placebo). The primary outcome measure is percent change from baseline in lumbar bone mineral density (BMD) at 12 months of treatment. Besides, percent change of lumbar BMD at 6 months, percent change of total hip and femoral neck BMD at 12 months, and the incidence of new fracture at 12 months will be evaluated. Biomarkers of s-CTX and PINP, PK evaluation of JMT103 serum drug concentration, immunogenicity evaluation of ADA and Nab, and adverse events will be also collected.

03

Conditions studied

  • Glucocorticoid Induced Osteoporosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Both genders aged 18 years or above, capable of autonomous action;
    1. In the course of an ongoing treatment for at least 3months with prednisone≥7.5 mg or its equivalent taken currently, and expected to be treated of no less than 6 months in total;
    1. Any of the followings: a. History of osteoporotic fracture; b. Age≥50 years and lumbar (L1-L4) or total hip BMD of T≤-2.0 by DXA; c. Age≥40 years and a predicted 10-year risk of major osteoporotic fractures ≥ 10% (vertebral body, forearm, hip, shoulder) or a predicted 10-year risk of hip fracture ≥ 1% estimated by hormone adjusted FRAX;
    1. At least two lumbar vertebrae from L1 to L4 evaluable by DXA;
    1. Uncompromised ability to maintain good communication with investigator and comply with all required study procedures;
    1. A signed under the capability of thorough understanding.

Exclusion criteria

Exclusion Criteria:

    1. Currently pregnant or lactating; For those of child bearing potential, refusal to use effective forms of from signing to 6 months after last administration;
    1. Previous or ongoing osteomyelitis or necrosis of jaw; Unhealed dental/oral operation wound; Acute jaw bone or dental disease requiring oral surgery; Planned invasive dental surgery during the study period;
    1. Selected into other clinical studies of which the latest administration is less than 4 weeks (or 5 elimination half-lives, whichever is longer) from the first administration in this study;
    1. Intravenous use of bisphosphonates, fluoride or strontium in the past 5 years; Oral bisphosphonates use for more than 3 years in total, or between 3 months to 3 years in total with the last medication used in the past 1 year prior to signing informed consent;
    1. Receptor Activator for Nuclear Factor-κ B Ligand (RANKL) antibody used within 6 months prior to screening;
    1. Administration of any of the following bone metabolism affecting drugs within 3 months prior to screening: a. Parathyroid hormone (PTH) or PTH derivatives (e.g., teriparatide); b. Anabolic hormones or testosterone; c. Sex hormone replacement; d. Selective estrogen receptor modulators (SERMs, e.g., raloxifene); e. Calcitonin; f. Other bone metabolism activating drugs include anticonvulsants (except benzodiazepines) and heparin; g. Long-term systemic use of ketoconazole, adrenocorticotropic hormone (ACTH), cinacalcet, aluminium, lithium, protease inhibitor, methotrexate or gonadotropin releasing hormone agonist;
    1. Administration of any of the following biologic agents within 4 weeks prior to screening: a. Anti-alpha 4 integrin antibody (e.g., natalizumab); b. Anti CD4/CD8 T-cells (e.g., alefacept); c. Anti-IL12/anti-IL23 (e.g., ustekinumab); d. CTLA4 inhibitor (e.g., abatacept); e. IL1 receptor antagonist (e.g., anakinra); f. IL6 inhibitor (e.g., tocilizumab); g. Monoclonal antibody to CD20 (e.g., rituximab); h. TNF antagonist (e.g., adalimumab, certolizumab, golimumab, etanercept, infliximab);
    1. Requirement of >1 biologic agent (other than trial drug) for the treatment of underlying inflammatory disease;
    1. Bone metabolic disorders (other than osteoporosis alone): a. Hypo- or hyperparathyroidism; b. Osteogenesis imperfecta; c. Malignant tumor; d. Hypopituitarism; e. Hyperprolactinemia; f. Acromegaly; g. Paget disease of bone;
    1. Hyperthyroidism or hypothyroidism, except for a stable replacement therapy for at least 3 months turning out a normal ranged TSH or increased TSH≤10.0 μIU/mL with normal ranged FT4;
    1. Malabsorption syndrome or various gastrointestinal diseases associated with malabsorption, such as Crohn's disease and chronic pancreatitis
    1. Liver cirrhosis or unstable liver disease (defined as ascites, hepatic encephalopathy, coagulation disorder, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice); Known or biliary abnormalities judged by investigator (except Gilbert syndrome, asymptomatic gallstones and gallbladder polyps);
    1. Previous organ or bone marrow transplantation;
    1. Unwilling to take vitamin D and calcium supplements as the procedure requires;
    1. Uncontrolled concurrent diseases, including but not limited to: uncontrolled diabetes (> 2 grade according to NCI-CTCAE5.0), symptomatic congestive heart failure, hypertension with blood pressure greater than 150/90 mmHg after standard treatment, unstable angina pectoris, arrhythmia requiring medication or instrument treatment, myocardial infarction history within 6 months, and echocardiography with \< 50%;
    1. 25[OH] vitamin D level \< 20 ng/mL, retest allowed after 5000 iu/day vitamin D added for 4-6 weeks;
    1. Current hypocalcemia or hypercalcemia, defined as albumin-corrected serum calcium level of ≤ 2.2 mmol/L (8.8 mg/dL) or ≥ 2.9 mmol/L (11.5 mg/dL) (no supplementation of calcium for at least 8 hours before test);
    1. Serum whole parathyroid hormone (iPTH) > 65 pg/mL;
    1. Any of the followings: a. Routine blood test (shall no treatment such as blood transfusion or hematopoietic stimulating factor was received within 7 days): \< 1.5×10\^9/L, \< 75 × 10\^9/L, or \< 90 g/L; b. Liver function test: total > 1.5 × value (ULN), (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN (retest allowed after 2-4 weeks for AST and ALT); c. Renal function test: estimated (eGFR) \< 35 L/(min·1.73m\^2); d. Coagulation function test: > 1.5 × ULN, or international normalized ratio (INR) > 1.5 × ULN;
    1. Active bacterial or fungal infections requiring systematic treatment within 7 days prior to randomization;
    1. infection, active hepatitis, known or suspected active tuberculosis;
    1. Any malignant tumor within 5 years prior to screening, except those expected to be cured (e.g., completely resected in situ skin basal cell or squamous cell carcinoma, cervical cancer or breast ductal cancer, etc.);
    1. Known allergic/hypersensitive reaction or intolerance to JMT103, positive control drug, calcium and vitamin D;
    1. to alendronate therapy: abnormalities of the esophagus which delay esophageal emptying (e.g., stricture or achalasia), or inability to stand or sit upright for at least 30 minutes;
    1. BMD measurement by DXA interrupted: \< 2 measurable lumbar vertebrae; Interrupting height, weight or waist circumference; Severe scoliosis and other measurement affecting conditions;
    1. Considered unsuitable for the research project by investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
231 participants (estimated)

Study arms

  • Experimental
    JMT103 60 mg group

    Patients will be administrated with JMT103 60 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).

    Drug: JMT103 · Drug: Alendronate sodium placebo

  • Experimental
    JMT103 90 mg group

    Patients will be administrated with JMT103 90 mg subcutaneously every 6 months (Q6W) and alendronate sodium tablet placebo once every week (QW).

    Drug: JMT103 · Drug: Alendronate sodium placebo

  • Active comparator
    Alendronate sodium group

    Patients will be administrated with alendronate sodium tablet orally 70 mg weekly (QW) and JMT103 placebo subcutaneously every 6 months (Q6W).

    Drug: Alendronate sodium · Drug: JMT103 placebo

Interventions

  • DrugNarlumosbartStudies of NarlumosbartNarlumosbart pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JMT103, subcutaneous injection, once every 6 months (Q6M)

  • DrugAlendronateStudies of AlendronateAlendronate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Alendronate sodium tablet, once every week (QW)

  • DrugJMT103 placebo

    JMT103 placebo, subcutaneous injection, once every 6 months (Q6M)

  • DrugAlendronate sodium placebo

    Alendronate sodium tablet placebo, once every week (QW)

06

What researchers measure

Primary outcomes

  1. Change rate of lumbar bone mineral density (BMD) from baseline at 12 months

    Time frame: 12 months

Secondary outcomes

  1. Change rate of lumbar spine BMD from baseline at 6 months

    Time frame: 6 months

  2. Change rate of total hip and femoral neck BMD from baseline at 12 months

    Time frame: 12 months

  3. Change rate of serum type I collagen cross-linked C-terminal peptide (s-CTX) and procollagen type I N-terminal propeptide (PINP) from baseline at 1, 3, 6 and 12 months

    Time frame: 1, 3, 6 and 12 months

  4. Incidence of new fractures at 12 months (vertebral and non-vertebral)

    Time frame: 12 months

  5. Types and proportions of adverse events

    Time frame: signing informed consent - 6 months after the last administration

  6. JMT103 serum drug concentration

    Time frame: Day 1 - 12 months

  7. Incidence of JMT103 anti-drug antibodies (ADA) and neutralizing antibodies (Nab)

    Time frame: Day 1 - 12 months

07

Study locations

1 site
  • Peking University First Hospital
    Beijing, Beijing 100034, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Jul 2022, 0 months later.

Of 42 phase 2 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2022
First posted
May 31, 2022
StartEst.
Jun 15, 2022
Primary completionEst.
Jul 1, 2022
CompletionEst.
Jun 1, 2023
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05397938
Responsible party
Sponsor
First posted
May 31, 2022
Start date
Jun 15, 2022 (estimated)
Primary completion
Jul 1, 2022 (estimated)
Completion
Jun 1, 2023 (estimated)
Last update
May 31, 2022

Study contacts

Shunqiang He
Contact
heshunqiang@mail.ecspc.com
+86-010-63398491

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Narlumosbart

Start the discussion